1. Home
  2. SPCE vs AGEN Comparison

SPCE vs AGEN Comparison

Compare SPCE & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Virgin Galactic Holdings Inc.

SPCE

Virgin Galactic Holdings Inc.

HOLD

Current Price

$3.14

Market Cap

331.6M

ML Signal

HOLD

Logo Agenus Inc.

AGEN

Agenus Inc.

HOLD

Current Price

$7.24

Market Cap

274.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPCE
AGEN
Founded
2017
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Transportation Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
331.6M
274.8M
IPO Year
2017
1999

Fundamental Metrics

Financial Performance
Metric
SPCE
AGEN
Price
$3.14
$7.24
Analyst Decision
Hold
Buy
Analyst Count
5
2
Target Price
$3.06
$14.50
AVG Volume (30 Days)
8.8M
8.2M
Earning Date
05-14-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
60.84
100.00
EPS
N/A
1.02
Revenue
$1,544,000.00
$42,877,086.00
Revenue This Year
$2,270.73
$107.63
Revenue Next Year
$880.03
N/A
P/E Ratio
N/A
$7.34
Revenue Growth
N/A
89.95
52 Week Low
$2.13
$2.71
52 Week High
$8.90
$8.85

Technical Indicators

Market Signals
Indicator
SPCE
AGEN
Relative Strength Index (RSI) 54.08 66.62
Support Level $2.84 $3.09
Resistance Level $3.34 $8.70
Average True Range (ATR) 0.17 0.74
MACD 0.08 0.12
Stochastic Oscillator 84.38 65.22

Price Performance

Historical Comparison
SPCE
AGEN

About SPCE Virgin Galactic Holdings Inc.

Virgin Galactic Holdings Inc is a United States-based vertically integrated aerospace company pioneering human spaceflight for private individuals & researchers, and it also manufactures air and space vehicles. Using technologies, the company is developing a spaceflight system designed to offer its customers a multi-day and transformative experience. This culminates in a spaceflight that includes views of Earth from space and several minutes of weightlessness that will launch from Spaceport America, New Mexico.

About AGEN Agenus Inc.

Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.

Share on Social Networks: